Anzeige
Mehr »
Login
Sonntag, 19.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
100-Milliarden-Dollar-Marke: Wie die strategische Vision eines Unternehmens historischem Meilenstein passt!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
396 Leser
Artikel bewerten:
(2)

Favo Capital, Inc.: FAVO Capital & Stewards Investment Capital Win Prestigious Global Finance Award

Finanznachrichten News

WESTBURY, NY / ACCESSWIRE / May 22, 2024 / Stewards Investment Capital, a boutique investment management and advisory firm and FAVO Capital's its strategic partner, have been recognized by Global Finance for the Best Fixed Income Investment Innovation Award as part of their Annual Top Innovation in Finance Awards for 2024.

This accolade highlights Stewards Investment Capital's groundbreaking APEX Structured Liquidity Solution, an investment product linked to the burgeoning private credit market in which FAVO Capital plays a major role.

Global Finance's eleventh annual Innovators Awards program celebrates entities across various categories, including banks, companies, and fintechs, that consistently pioneer new paths and develop innovative financial tools. The APEX Structured Liquidity Solution by Stewards Investment Capital was recognised for its unmatched innovation, effectiveness, and impact in diversifying investment options for its investors.

Global Finance was founded in 1987, audited by BPA, and readers in 192 countries. Its headquarters are in New York, with offices in London and Milan. Each year Global Finance selects the best financial institutions around the world and these awards have become a recognized and trusted standard of excellence. Past winners include HSBC, DBS, Citi, Standard Bank, BNP Paribas, Societe General, First Abu Dhabi Bank, Nedbank, ABSA amongst others.

Stewards Investment Capital's award-winning APEX Structured Liquidity Solution represents a paradigm shift in fixed income investments, offering investors a unique and dynamic approach to managing liquidity while maximizing returns. Through the use of cutting-edge technology, advanced risk management strategies, and a profound understanding of market dynamics, Stewards Investment Capital together with FAVO Capital have developed a solution that not only delivers superior performance but also substantial value to its investors.

Joseph Giarraputo, founder and editorial director of Global Finance, noted, "Innovation continues to help banks and other financial institutions gain a strategic competitive advantage. By embracing new technologies and creative approaches, this year's winners have crafted groundbreaking solutions that ease customer pain points and deliver exceptional user experiences."

Glen Steward, Founder and Chairman of Stewards Investment Capital and Chief Strategy Officer and Board member of FAVO Capital Inc., expressed his gratitude, stating, "We are humbled and thankful to Global Finance for this honor and recognition. I would also like to thank our dedicated team at Stewards and FAVO Capital, whose relentless efforts ensure that our investors' money works harder everyday. Mr. Steward added, "This award is a testament to our continued commitment to innovation."

Shaun Quin, President at FAVO Capital Inc., remarked, "We are incredibly proud to see Stewards recognized for their groundbreaking work with the APEX Structured Liquidity Solution. Steward's ability to navigate and lead within the evolving private credit market aligns perfectly with FAVO Capital's mission to support innovative financial solutions. Congratulations to Glen Steward, Bilal Adam, and the entire team at Stewards Investment Capital for this well-deserved award."

Bilal Adam, CEO of Stewards Investment Capital, added, "This prestigious award is a testament to our commitment to innovation and excellence while providing investors the opportunity to diversity their portfolio in emerging asset classes such as private credit." He added. "Our Apex Structured Liquidity Solution is a low-risk cash management solution offering fixed income returns in USD. Besides the attractive yearly returns, this solution has no mark-to-market volatility and options for monthly liquidity, making it even more attractive for investors."

More About FAVO Capital, Inc.

FAVO Capital, Inc. (OTC Pink:FAVO) is a rapidly growing direct funding company headquartered in USA. With extensive expertise in business, entrepreneurship and finance, their dedicated professionals offer a range of personalised funding solutions to emerging, small, and medium-sized businesses. FAVO's goal is to facilitate swift and efficient funding without imposing rigid requirements, enabling businesses to grow in a seamless manner.

Their services include Merchant Cash Advance (MCA), Invoice financing, Equipment financing, Business lines of credit, Small Business Administration (SBA) loans and Real estate backed bridge financing.

FAVO Capital Inc. employs over 120 people in 5 offices globally.

About Stewards Investment Capital

Stewards Investment Capital is boutique investment advisory leader with a 25-year legacy within the Stewards affiliation of companies. With a strategic presence in Mauritius, South Africa and USA, they specialize in tailoring niche investment solutions with optimized risk adjusted returns for high-net-worth individuals, pension funds and institutional investors.

The Stewards affiliation of companies has multiple financial services licenses and business in South Africa, Mauritius and USA with operations spanning forex, trade finance, investment management, micro finance, private credit, payments, market maker and liquidity provider. https://www.stewardsinvestment.com

Watch Our Corporate video here: https://tinyurl.com/4kvw3nk2

Contact:

Email: info@favocapital.com
Tel: 833.328.6477
Website: www.favocapital.com

Safe Harbor/Forward-Looking Statements

This press release contains certain forward-looking statements including, but not limited to, statements, estimates, and projections of future trends and of the anticipated future performance constitute "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933, as amended, including, without limitation, statements regarding the Series' expectations, beliefs, or future strategies that are signified by the words "expects," "anticipates," "intends," "believes," or similar language. These forward-looking statements concern the Company's operations, economic performance and financial condition and are based largely on the Company's beliefs and expectations. These statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Actual results may differ materially from expected results. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of this press release FAVO Capital, Inc and its Management Team expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or regulation.

SOURCE: FAVO Capital, Inc.



View the original press release on accesswire.com

© 2024 ACCESS Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.